Pathology’s Precision Oncology Mandate

Advances in bladder cancer treatment focus on precision medicine.

Genetic biomarkers via NGS are crucial for guidance.

PD-L1 and FGFR3 tests are highlighted in guidelines.

Collaboration among specialists is essential.

Challenges include testing disparities and delays.

Rapid testing may enhance accessibility.

Pathologists play a key role in interpreting genetic tests.

Future care requires speed, collaboration, and education.